论文部分内容阅读
在抗肿瘤药物的发展过程中,有很多具有里程碑意义的事件,分子靶向治疗公认是最新的里程碑。自从1965年美国临床肿瘤学会成立标志着临床肿瘤学成为临床医学的分支以来,内科肿瘤学发展迅速在常见肿瘤综合治疗的地位也越来越重要。WHO关于肿瘤属于可控慢性病的论述和分子靶向治疗的迅速发展,使临床肿瘤治疗的策略有了本质性的变革。从抑制生长活跃的细胞增殖,转变到以阻断肿瘤发生发展和转导过程中的分子生物学事件包括基因、受体、生长因子和激酶等为目标,而且越来越个体化,从而达到阻断癌变和增殖,或使迅速生长的肿瘤发展变成慢性过程,患者保持良好的生活质量和正常工作。从中医辨证论治基本原则来说,个体化是疾病疗效提高的必然途径。而中医“同病异治”和“异病同治”的实践恰好使今天的靶向治疗得到最好的诠释。
There are many landmark events in the development of anticancer drugs, and molecular targeted therapy is the most recent milestone. Since the establishment of the American Society of Clinical Oncology in 1965 marked a branch of clinical oncology as a clinical medicine, the rapid development of medical oncology has become increasingly important in the treatment of common oncological diseases. The WHO’s statement that tumors are controlled chronic diseases and the rapid development of molecular targeted therapy have revolutionized the strategy of clinical oncology treatment. From inhibiting growth-active cell proliferation to target molecular biology events that block the development and transduction of tumors including genes, receptors, growth factors and kinases, and are increasingly individualized to achieve resistance Breaking cancerous and proliferating, or turning rapidly growing tumors into chronic processes, patients maintain good quality of life and work properly. From the basic principles of TCM diagnosis and treatment, individualization is the inevitable way to improve the efficacy of the disease. The practice of traditional Chinese medicine “treating different diseases with different diseases” and “treating different diseases with the same disease” exactly gives the best interpretation of today’s targeted treatment.